See Bull Run's live company pages for Dr Reddy's Laboratories and Lupin. Investors can also compare Dr Reddy's with another respiratory-heavy Indian peer in Bull Run's Dr Reddy's vs Cipla comparison.

The topline gap was less than 2%.

The EBITDA gap was more than 150%.

Q1 FY27 financial scorecard

Dr Reddy's Q1 was hit by two separate problems at once

The first was expected.

The second was not.

Dr Reddy's had spent several years benefiting from lenalidomide economics in the United States.

That period ended as the commercial arrangement and competitive landscape changed.

North America therefore entered FY27 with a materially lower revenue and margin base.

At the same time, certain semaglutide batches were found to be out of specification because of an issue associated with the API.

The semaglutide provision cost ₹239.7 crore

Reported EBITDA margin was 12.5%.

Excluding the semaglutide API impact, management calculated EBITDA margin at approximately 15.4%.

That is clearly better than the headline figure.

But it remains far below Lupin's 31.4%.

The conclusion is important: the semaglutide provision explains part of Dr Reddy's weakness, not all of it.

Lenalidomide had a much larger structural effect

Dr Reddy's North America revenue fell approximately 35% to ₹2,205 crore.

Management explicitly identified lower lenalidomide sales as the main reason.

This demonstrates one of the fundamental risks of limited-competition US generics.

A product can earn extraordinary profit for several years.

When exclusivity or commercial advantage ends, revenue and margin can reset very quickly.

Lupin is currently enjoying the other side of that cycle

That was approximately 56% more US revenue than Dr Reddy's generated in North America.

Lupin's growth came from a combination of:

• complex generic launches;
• limited-competition products;
• respiratory products;
• long-acting injectables;
• improved product mix;
• market-share gains.

Lupin's US portfolio is becoming harder to replicate

Lupin has been deliberately moving away from the simplest generic tablets.

Its portfolio increasingly includes products where development or manufacturing is difficult.

Examples include inhaled therapies, depot injections, injectables and biosimilars.

These categories can reduce the number of competitors and support better pricing.

That helps explain why gross margin reached 74.6% and EBITDA margin exceeded 31%.

But Lupin also faces normalization risk

The current quarter should not be viewed as risk-free.

First-to-file and limited-competition products can lose profitability when rivals enter.

For Lupin to sustain today's economics, it must continually replace maturing opportunities with new launches.

That is why the pipeline matters as much as the current income statement.

Lupin has 50 first-to-file filings

During Q1, Lupin received six US FDA ANDA approvals and launched three products.

It marketed 149 generic products in the US.

According to company-cited IQVIA data, Lupin remained the third-largest pharmaceutical player in the US generic market by prescriptions.

That gives it both pipeline depth and commercial scale.

Dr Reddy's pipeline is also substantial

Dr Reddy's had 79 filings pending US FDA approval at June 30.

They included:

• 76 ANDAs;
• 45 Paragraph IV applications;
• 24 applications that may have first-to-file status;
• three 505(b)(2) NDAs.

The company launched six new products in North America during Q1.

It also launched Bosutinib 400 mg as a first-to-market product with 180 days of generic exclusivity.

Dr Reddy's therefore still has US optionality

The Q1 revenue decline does not mean its North American franchise is broken.

The company is attempting to replace lenalidomide with a broader mix of:

• peptides;
• biosimilars;
• complex generics;
• 505(b)(2) products;
• innovative partnered assets.

The difficult part is timing.

Pipeline value appears in earnings only after regulatory approval, launch and commercial adoption.

Dr Reddy's underlying base business was actually growing

Management said that excluding lenalidomide, the underlying base business delivered healthy double-digit growth across all key geographies, including North America.

This is an important distinction.

Reported revenue fell because a very large high-value product disappeared.

The rest of the business was not shrinking.

That supports the recovery thesis.

India grew faster for Dr Reddy's

Dr Reddy's India revenue reached approximately ₹1,718 crore and grew 17% year on year.

Lupin India sales reached approximately ₹2,380 crore and grew 13.9%.

So Lupin had the larger domestic business, but Dr Reddy's grew faster.

Dr Reddy's is gaining Indian pharmaceutical share

Company-cited IQVIA data showed Dr Reddy's secondary sales growth outperforming the Indian pharmaceutical market.

During Q1 it launched seven new brands.

Recent growth also benefited from acquired portfolios and in-licensed innovative assets.

Toripalimab, an in-licensed oncology therapy, crossed ₹100 crore of revenue in less than two years after launch.

That changes Dr Reddy's India business model

Historically, Indian pharmaceutical companies often relied mainly on conventional branded generics.

Dr Reddy's is increasingly adding:

• in-licensed innovative therapies;
• consumer health;
• specialty medicines;
• metabolic products;
• acquired brands.

This can increase revenue per physician relationship and reduce dependence on conventional generic launches.

Lupin's India portfolio has greater scale

Lupin generated ₹2,380 crore of India sales.

India represented 29% of global sales.

The company launched seven brands during the quarter and is currently the eighth-largest company in the Indian pharmaceutical market according to company-cited IQVIA data.

Its increasing chronic-therapy mix is particularly important.

Emerging markets currently favour Dr Reddy's absolute scale

Dr Reddy's Emerging Markets revenue reached approximately ₹1,833 crore and grew 31%.

Russia alone generated approximately ₹900 crore.

Lupin's Emerging Markets revenue was approximately ₹990 crore and grew 51.7%.

Dr Reddy's therefore has greater absolute emerging-market scale, while Lupin is currently growing faster.

Europe is another Dr Reddy's strength

Europe generated approximately ₹1,444 crore and grew 13%.

Germany and the UK both delivered strong growth.

The business also includes the acquired Nicotine Replacement Therapy portfolio.

Dr Reddy's branded businesses—India, Emerging Markets and the acquired NRT portfolio—now account for 52% of consolidated revenue.

That 52% branded mix reduces reliance on US generics

This is a strategic positive.

US generic earnings can be volatile because of price erosion and exclusivity cliffs.

Branded emerging-market and India businesses can provide more durable pricing and prescription economics.

The challenge is that branded businesses require more selling expenditure.

Dr Reddy's SG&A reached 35.7% of revenue

Selling, general and administrative expenses increased 12% to approximately ₹2,882 crore.

They represented 35.7% of revenue versus 30% a year earlier.

Management cited:

• higher personnel costs;
• currency effects;
• targeted branded-business investment;
• higher freight costs linked to Middle East disruption.

This explains why base-business growth did not translate into stronger consolidated EBITDA.

Lupin's operating leverage is currently much better

Lupin's personnel costs represented 16.8% of sales.

Manufacturing and other expenses represented 28.5%.

Its favourable gross margin and product mix allowed a much larger percentage of revenue to reach EBITDA.

That creates today's 31.4% margin.

R&D intensity is almost identical

Dr Reddy's spent ₹577 crore, or 7.1% of revenue.

Lupin spent ₹608 crore, or 7.4% of sales.

This similarity is important.

Lupin is not producing its higher margin simply by starving the pipeline.

Both companies are investing materially in future products.

The research priorities differ

Dr Reddy's R&D remains focused on complex generics, peptides, biosimilars and innovative assets.

Lupin's R&D focuses heavily on complex US opportunities, respiratory products, injectables, biosimilars and specialty platforms.

The eventual winner will be determined by return on R&D rather than the absolute rupee spend.

Dr Reddy's semaglutide issue is also a quality-control warning

The company found certain semaglutide batches out of specification because of an API-related issue.

It has taken measures to resume supplies.

This episode demonstrates a broader pharmaceutical truth:

manufacturing quality is part of the investment thesis.

A single quality event can affect inventory, supply, margin and customer confidence simultaneously.

There is another regulatory item to monitor

Dr Reddy's biologics facility at Bachupally received a US FDA Form 483 with seven observations after a pre-license inspection in June 2026.

The company said it responded within the required timeline.

A Form 483 is not the same as a warning letter, but the observations remain an execution item to monitor because biologics are an important future growth area.

Balance sheets are healthy for both

Dr Reddy's Q1 return on capital collapsed—but that is not the trailing picture

Dr Reddy's company-reported annualised Q1 ROCE was only 5.3%.

Excluding the semaglutide impact, it was approximately 8%.

Bull Run's standardized trailing ROCE field remains around 14.8% because it incorporates a broader earnings period.

This distinction matters.

Q1 annualised ROCE shows how weak the quarter was.

Trailing ROCE shows the underlying company has historically earned more than the Q1 run rate.

Lupin's current capital returns are much stronger

Lupin leads dramatically on the current standardized return ratios.

Dr Reddy's has generated more cumulative five-year free cash flow, which shows why one difficult quarter should not erase its longer-term quality.

Valuation currently reinforces Lupin's operating lead

Lupin trades at a much lower P/E despite generating much stronger current earnings.

Its price-to-book is higher because current return on equity is also much higher.

Dr Reddy's lower price-to-book reflects the market's weaker expectations for near-term returns.

Why is Dr Reddy's not cheaper on P/E?

Because trailing earnings still contain stronger earlier quarters.

The Q1 collapse has not yet fully flowed through a trailing-twelve-month denominator.

More importantly, investors are pricing a recovery rather than assuming 12.5% EBITDA margin is permanent.

If future earnings remain near Q1 levels, Dr Reddy's valuation would look much more demanding.

Lupin's 20.6x P/E also contains normalization risk

The low multiple does not mean current earnings are guaranteed.

Limited-competition products can lose value.

Taxes can normalize.

Gross margin can fluctuate.

The market is therefore applying a discount to the possibility that current US profitability represents a particularly strong part of the cycle.

The valuation question is really about normalized earnings

For Dr Reddy's, investors must estimate profit after:

• the semaglutide provision disappears;
• lenalidomide has fully normalized;
• new products contribute;
• freight and solvent pressure eases.

For Lupin, investors must estimate profit after:

• current exclusivity products mature;
• new complex products replace them;
• the tax rate normalizes;
• biosimilar investment scales.

What must Dr Reddy's prove?

• North America base-business growth must offset the lenalidomide reset.
• Semaglutide supply and quality issues need complete resolution.
• EBITDA margin must recover materially above Q1's 12.5%.
• India and Emerging Markets should sustain double-digit growth.
• The 79-product US pending pipeline needs profitable approvals.
• Biologics regulatory observations must be resolved satisfactorily.
• New peptide and innovative assets need commercial traction.

What must Lupin prove?

• Current US growth must survive exclusivity normalization.
• Complex generics should remain a rising share of US revenue.
• 31%-plus EBITDA margin must prove reasonably sustainable.
• India needs continued double-digit growth.
• Biosimilars and specialty investments should generate attractive returns.
• New launches need to replenish maturing products.
• ROCE should remain high through the next product cycle.

What could make Dr Reddy's outperform Lupin?

A sharp recovery from an unusually depressed earnings base.

If semaglutide provisions disappear, logistics costs normalize and new launches replace part of lenalidomide, Dr Reddy's EBITDA can grow far faster than revenue.

Its branded businesses are already growing.

The operating leverage could therefore be substantial.

What could make Lupin outperform Dr Reddy's?

Continued differentiated-product execution without major normalization.

If Lupin keeps introducing complex generics quickly enough to replace maturing opportunities, a 20.6x P/E is much easier to support than Dr Reddy's current multiple.

Which has the stronger US business today?

Lupin.

Q1 US sales were approximately ₹3,435 crore and grew 42.9%, versus Dr Reddy's North America revenue of ₹2,205 crore, down 35%.

Which has the stronger India business?

Lupin on absolute Q1 revenue.

Lupin generated approximately ₹2,380 crore compared with Dr Reddy's at ₹1,718 crore.

Dr Reddy's grew faster at 17% versus Lupin at 13.9%.

Which has the stronger current pipeline?

There is no simple winner.

Lupin has more marketed US generic scale and 50 first-to-file filings.

Dr Reddy's has 79 US applications pending, including substantial Paragraph IV and possible first-to-file opportunities, plus peptides, biosimilars and partnered innovative assets.

Which has the stronger current valuation?

Lupin.

Its P/E is roughly 20.6x versus Dr Reddy's at 31.9x while current ROCE and operating profitability are much stronger.

Which is better: Dr Reddy's or Lupin?

Lupin currently has the stronger valuation-adjusted operating profile. The two companies generated almost identical Q1 sales, but Lupin produced more than 2.5 times the EBITDA, more than three times attributable PAT, stronger US growth and substantially higher ROCE while trading at a lower P/E.

Dr Reddy's is the more interesting recovery case. Its Q1 simultaneously absorbed the post-lenalidomide reset and a ₹239.7 crore semaglutide provision, while the underlying business still grew double digits across key geographies.

The investment question is therefore not whether Dr Reddy's Q1 was weaker—it clearly was.

The question is how quickly normalized margins recover.

At September 2026 valuations, Lupin is the stronger current combination of growth, profitability and value. Dr Reddy's can close the gap if its pipeline replaces lenalidomide, semaglutide quality issues are resolved and EBITDA returns toward a materially higher normalized range.

Frequently asked questions